Access Uncertain for New Injectable PrEP as the Affordable Care Act’s (ACA) Open Enrollment Begins
Background In June 2025, the Food and Drug Administration (FDA) approved lenacapavir (Yeztugo) as the latest pre-exposure prophylaxis (PrEP) drug to prevent HIV in adults and adolescents. Lenacapavir differs from other available PrEP products. It is the second long-acting injectable PrEP drug on the market but offers less frequent (twice annual) dosing. Its relatively infrequent…


